AZACITIDINE IN COMPARISON TO INTENSIVE CHEMOTHERAPY AND BEST SUPPORTIVE CARE IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA, A DATAML REGISTRY STUDY

EHA Library, Noémie Gadaud, 325216

A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

EHA Library, Courtney DiNardo, 325217

INDUCED SYSTEMIC T-CELL SPECIFIC RESPONSES TO MULTIPLE TUMOR-ASSOCIATED ANTIGENS AFTER ALLOGENIC LEUKEMIA-DERIVED DENDRITIC CELL VACCINE DCP-001 IN AML PATIENTS WITH PERSISTENT MRD

EHA Library, Hester J.T. Van Zeeburg, 325218

PROGNOSTIC IMPACT OF MINIMAL REDISUAL DISEASE ASSESSMENT IN ELDERLY PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA. A COMPARISON BETWEEN CPX-351 AND INTENSIFIED FLUDARABINE-BASED REGIMENS

EHA Library, Fabio Guolo, 325219

ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION WAS SUPERIOR TO CONSOLIDATION CHEMOTHERAPY IN HIGH-RISK CN-AML WITH BIALLELIC CEBPA MUTATIONS BASED ON A MUTI-GENE PANEL AND NOMOGRAM MODEL

EHA Library, Li-Xin Wu, 325220

N-TERMINAL FRAGMENT OF BRAIN NATRIURETIC PEPTIDE (PBNP) IS A NOVEL INDEPENDENT PROGNOSTIC MARKER FOR SURVIVAL AND RESPONSE TO INTENSIVE CHEMOTHERAPY IN AML

EHA Library, Irene Graf, 325221

EFFICACY AND SAFETY OF ASPACYTARABINE (BST-236) AS A FIRST-LINE MONOTHERAPY FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD CHEMOTHERAPY

EHA Library, Jessica K. Altman, 325222

THE COMBINATION OF AXL INHIBITOR BEMCENTINIB AND LOW-DOSE CYTARABINE IS WELL TOLERATED AND EFFICACIOUS IN ELDERLY RELAPSED AML PATIENTS: UPDATE FROM THE ONGOING BGBC003 PHASE II TRIAL (NCT02488408)

EHA Library, Sonja Loges, 325223

TRIPLE COMBINATION OF HMA, VENETOCLAX, AND FLT3 INHIBITOR PRODUCES HIGHER FLT3 PCR CLEARANCE, FLOW MRD NEGATIVITY, AND IMPROVED MEDIAN OS COMPARED WITH DOUBLETS OF HMA WITH FLT3 INHIBITOR

EHA Library, Musa Yilmaz, 325224

UPDATED PHARMACODYNAMIC AND SURVIVAL OUTCOMES FROM THE AG221-AML-005 TRIAL OF ENASIDENIB (ENA) PLUS AZACITIDINE (AZA) IN PATIENTS WITH MUTANT IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML)

EHA Library, Courtney DiNardo, 325225

PROGNOSTIC VALUE OF CRH IN ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX AND DECITABINE

EHA Library, Maria Siddiqui, 325226

ACTIVITY OF DECITABINE COMBINED WITH ALL-TRANS RETINOIC ACID IN OLIGOBLASTIC AML: RESULTS FROM A RANDOMIZED 2X2 PHASE II TRIAL

EHA Library, Christoph Rummelt, 325227

FLT3 INHIBITOR BASED INDUCTION AND ALLOGENEIC STEM CELL TRANSPLANT IN CR1 IMPROVE OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED AML VERY LOW FLT3 ALLELIC BURDEN

EHA Library, Musa Yilmaz, 325228

RE-STRATIFYING THE PROGNOSES OF ACUTE MYELOID LEUKEMIA PATIENTS WITH CEBPA DOUBLE MUTATIONS BY CSF3R MUTATIONS AND MINIMAL RESIDUAL DISEASE

EHA Library, SuJun Gao, 325229

SUPERIOR OUTCOMES FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST REMISSION FOR NPM1/FLT3-ITD MUTATED AML

EHA Library, Callum Wright, 325230

EFFICACY AND SAFETY OF ENASIDENIB AND AZACITIDINE COMBINATION IN PATIENTS WITH IDH2 MUTATED ACUTE MYELOID LEUKEMIA AND NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

EHA Library, Sangeetha Venugopal, 325231

REAL-LIFE PRELIMINARY EXPERIENCE OF TREATMENT OF NEWLY-DIAGNOSED AND REFRACTORY/RELAPSED (R/R) ACUTE MYELOID LEUKEMIA PATIENTS WITH COMBINATION OF VENETOCLAX WITH HYPOMETHYLATING AGENTS

EHA Library, Carlos Jimenez-Vicente, 325232

PROGNOSTIC SIGNIFICANCE OF ACHIEVING A COMPLETE REMISSION AFTER ONE OR TWO CYCLES OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: ANALYSIS OF DATA FROM THE DATOOL-AML DATABASE

EHA Library, Lukas Semerad, 325233

SORAFENIB IN COMBINATION WITH INTENSIVE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A SINGLE-INSTITUTION EXPERIENCE

EHA Library, Irene Urbino, 325234

RISK FACTORS AND MANAGEMENT OF CATHETER-RELATED THROMBOSIS IN ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Netanel A. Horowitz, 325235

INVESTIGATING THE INCIDENCE OF SECONDARY PRIMARY CANCER IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS

EHA Library, Yu-Guang Chen, 325236

BCL-2 EXPRESSION IN ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS AND IMPACT ON OUTCOMES ACCORDING TO DIFFERENT THERAPEUTIC STRATEGIES

EHA Library, Mario Tiribelli, 325237

ABERRANT CD7 EXPRESSION IN PEDIATRIC ACUTE MYELOID LEUKEMIA: SIGNIFICANCE AND CLINICAL IMPLICATIONS

EHA Library, Fabiana Cacace, 325238

ENASIDENIB IN PATIENTS WITH IDH2-MUTATED ACUTE MYELOID LEUKEMIA (AML). A 'REAL LIFE' MULTI-CENTER EXPERIENCE FROM SPANISH HOSPITALS

EHA Library, Marina Diaz-Beya, 325239

CLI120-001 PHASE1B STUDY OF SEL120/RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS: PRELIMINARY CLINICAL AND PK RESULTS FROM INITIAL DOSE ESCALATION COHORTS

EHA Library, Noemi Angelosanto, 325240

A HOME CARE PROGRAMME FOR THE RAMP-UP AND FIRST COURSES OF TREATMENT WITH VENETOCLAX AND HYPOMETHYLATING AGENTS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Alexandra Martínez-Roca, 325241

INTERMEDIATE OR STANDARD DOSE CYTARABINE AS POST REMISSION THERAPY IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA: IMPACTS ON OUTCOMES AND HEALTH CARE RESOURCE CONSUMPTION

EHA Library, Jean Galtier, 325242

APPLICATION OF MACHINE LEARNING IN STRATIFYING MINIMAL RESIDUAL DISEASE LEVEL WITH FLOW CYTOMETRY IN ACUTE MYELOID LEUKEMIA

EHA Library, Bor-Sheng Ko, 325243

THE PROGNOSTIC SIGNIFICANCE OF FLT3 INTERNAL TANDEM DUPLICATIONS’ CHARACTERISTICS AND CO-MUTATIONS IN ACUTE MYELOID LEUKEMIA 

EHA Library, Lei-Ming Cao, 325244

SURVIVAL OUCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUCOCYTOSIS

EHA Library, Jonathan Sillar, 325245

GLASDEGIB IN COMBINATION WITH LOW DOSE CYTARABINE FOR ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS FAILING HYPOMETHYLATING AGENTS

EHA Library, Andrius Žučenka, 325246

GEMTUZUMAB OZOGAMICIN ADDED TO HIDAC CONSOLIDATION THERAPY FOR STANDARD-RISK ACUTE MYELOID LEUKEMIA IS SAFE AND EFFICACIOUS

EHA Library, Nurit Horesh, 325247

INDUCTION CHEMOTHERAPY WITH CYTARABINE, DAUNORRUBICIN AND ETOPOSIDE VERSUS STANDARD-DOSE CYTARABINE AND DAUNORRUBICIN IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Catia Reis, 325248

NEXT STEP AFTER COMPLETE REMISSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Claudia Nunez-Torron Stock, 325249

ROLE OF EXTRACELLULAR VESICLE-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS IN ACUTE MYELOID LEUKEMIA

EHA Library, Haizhou Xing, 325250

MULTICENTER OBSERVATIONAL RETROSPECTIVE STUDY ON BACTERIAL/FUNGAL/VIRAL INFECTIONS IN PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA TREATED WITH CPX-351 IN 'REAL-LIFE'

EHA Library, Luana Fianchi, 325251

DELAY IN THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA, COMPARISON BEFORE AND AFTER SARS-COV-2: A SINGLE CENTRE STUDY

EHA Library, Cristina Alburquerque-Prieto, 325252

AN UPDATE ANALYSIS OF PROGNOSTIC SIGNIFICANCE OF PERIPHERAL BLOOD BLASTS ON DAY 7 OF INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, SuJun Gao, 325253

IMPACT OF TREATMENT INTENSITY, MRD AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY R/R AML PATIENTS: A MONOCENTRIC RETROSPECTIVE STUDY

EHA Library, Zofia Gross, 325254

PROPHYLACTIC CORTICOSTEROID USE WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Olalekan O. Oluwole, MBBS, MPH, 325255

FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‑CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

EHA Library, David Belada, 325256

EARLY RESPONSE AT ONE MONTH IS PREDICTIVE OF THE OUTCOME OF THE PATIENTS WITH RELAPSE/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CAR T-CELL

EHA Library, Jean Galtier, 325257

CD19 CAR-T IN LESS FIT PATIENTS WITH R/R HIGH-GRADE LYMPHOMA

EHA Library, Andrea Kuhnl, 325258

SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: SAFETY PROFILE AND ANTI-TUMOR ACTIVITY

EHA Library, Rogier Mous, 325259

PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED MCL, WM AND OTHER NHLS: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

EHA Library, Nirav N Shah, 325260

GLOFITAMAB STEP-UP DOSING (SUD): UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL) PATIENTS (PTS)

EHA Library, Carmelo Carlo-Stella, 325261

IBRUTINIB, BENDAMUSTINE, RITUXIMAB FOR RELAPSED AND REFRACTORY AGGRESSIVE B CELL LYMPHOMA – FINAL ANALYSIS OF PHASE II CLINICAL TRIAL

EHA Library, Meirav Kedmi, 325262

MOSUNETUZUMAB (MOSUN) MONOTHERAPY FOR ELDERLY/UNFIT PATIENTS (PTS) WITH FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) CONTINUES TO SHOW PROMISING SAFETY AND EFFICACY WITH DURABLE COMPLETE RESPONSES

EHA Library, Adam Olszewski, 325263

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN PATIENTS OLDER THAN 65 YEARS: ANALYSIS OF 3 YEAR REAL WORLD DATA OF PRACTICE PATTERNS AND OUTCOMES IN ENGLAND

EHA Library, Toby Eyre, 325264

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CONDITIONING INCLUDING ALLOGENEIC BISPECIFIC CAR-T CELLS TARGETING BOTH CD19 AND CD22 FOR REFRACTORY/RELAPSED B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Fan Yang, 325265

ECHELON-2, (NCT01777152), 5-YEAR RESULTS OF A RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + CHP VS CHOP IN PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA

EHA Library, Eva Domingo Domènech, 325266

RELAPSE AND SURVIVAL POST-PROGRESSION IN LYMPHOMA PATIENTS AFTER STEM CELL TRANSPLANTATION

EHA Library, Ayumi Fujimoto, 325267

CRS AND ICANS RISK ACROSS THREE CD19 CAR-T CELL PRODUCTS IN PATIENTS WITH AGGRESSIVE NHL

EHA Library, Jordan Gauthier, 325268

EFFICACY AND SAFETY OF MOGAMULIZUMAB BY PATIENT BLOOD CLASSIFICATION

EHA Library, Julia Scarisbrick, 325269

COMPARATIVE EFFICACY OF TISAGENLECLEUCEL (TISA-CEL) AND LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

EHA Library, Marie José Kersten, 325270

PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP

EHA Library, Yassine Al Tabaa, 325271

INTRAVENOUS HIGH DOSE METHOTREXATE FOR PREVENTION OF CNS RELAPSE IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): REAL-WORLD OUTCOMES AND PRACTICE PATTERNS FROM CHINESE INSTITUTION

EHA Library, Qingqing Cai, 325272

COMPREHENSIVE GERIATRIC ASSESSMENT-DRIVEN TREATMENT DECISION VERSUS CLINICAL JUDGMENT IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA

EHA Library, Jie-Fei Bai, 325273

INFECTION-RELATED MORBIDITY AND MORTALITY FOR ELDERLY DLBCL PATIENTS TREATED WITH FULL OR ATTENUATED DOSE R-CHOP

EHA Library, Toby Eyre, 325274

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN KIDNEY TRANSPLANT PATIENTS: A MULTICENTER REPORT IDENTIFYING THE IMPORTANCE OF ALLOGRAFT PRESENTATION

EHA Library, Elise Chong, 325275

SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED ANALYSIS OF THE PHASE 1B PORTIA STUDY

EHA Library, Ulrich Jäger, 325276

INTERIM-PET IS NOT PREDICTIVE OF OUTCOME IN DLBCL PATIENTS WITH MYC REARRANGEMENTS DUE TO ABERRANT RESPONSE PATTERNS

EHA Library, Jakoba J. Eertink, 325277

DURATION OF RESPONSE TO LONCASTUXIMAB TESIRINE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS: SUBGROUP ANALYSES FROM LOTIS-2

EHA Library, Paolo F. Caimi, 325278

PROGNOSTIC SIGNIFICANCE OF TIME FROM LAST THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORDS AND CLAIMS DATA IN THE US

EHA Library, Michael Dickinson, 325279

PROGNOSIS AND HEPATIC TOXICITY IN HEPATITIS C VIRUS-POSITIVE PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Minyue Zhang, 325280

BASELINE TOTAL METABOLIC TUMOR VOLUME >220CM³ AND DEAUVILLE 5-POINT SCALE OF ≥4 AFTER FOUR CYCLES OF R-CHOP ARE STRONGLY ASSOCIATED WITH INFERIOR PROGRESSION FREE SURVIVAL IN PATIENTS WITH DLBCL

EHA Library, Eduard Schulz, 325281

THE IMPACT OF THE GERIATRIC 8 SCORE ON OVERALL SURVIVAL IN OLDER ADULTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

EHA Library, Kana Oiwa, 325282

DOES INTENSIVE CHEMOTHERAPY REALLY HELP OLDER DLBCL PATIENTS LIVE LONGER?

EHA Library, Dominic Gordon-Walker, 325283

PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

EHA Library, Anthony R. Mato, 325284

PRELIMINARY SAFETY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES TREATED WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417

EHA Library, Chan Y. Cheah, 325285

PATIENTS WITH OUT OF SPECIFICATION TISAGENLECLEUCEL CAN BE SALVAGED WITH POINT-OF-CARE CAR-T CELLS: AN OBSERVATIONAL INTENTION-TO-TREAT SINGLE-CENTER ANALYSIS

EHA Library, Shalev Fried, 325286

DISCOVERY OF HBW-3-20, THE FIRST REVERSIBLE INHIBITOR OF BRUTON’S TYROSINE KINASE (BTK) WITH HIGH BRAIN EXPOSURE

EHA Library, Chester Yuan, 325287

CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO RECEIVED ≥3 LINES OF THERAPIES

EHA Library, Laura Liao, 325288

REAL WORLD CLINICAL EFFECTIVENESS AND SAFETY OF CT-P10 IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY

EHA Library, Pier Luigi Zinzani, 325289

LYMPHOCYTE COUNT EFFECT ON EFFICACY AND SAFETY OF SINGLE AGENT ORAL SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A POST-HOC ANALYSIS FROM PHASE 2B SADAL STUDY

EHA Library, Michael Schuster, 325290

CLINICOPATHOLOGIC DESCRIPTORS OF MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA (MEITL): ANALYSIS OF A POOLED DATABASE OF A NEW ENTITY

EHA Library, Philip Haddad, 325291

POPULATION-BASED COHORT STUDY OF THE EFFICACY OF BRENTUXIMAB-VEDOTIN IN RELAPSED SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA USING PUBLIC HEALTH ENGLAND DATA

EHA Library, Sarah Halligan, 325292

COMBINED TREATMENT OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS TRANSPLANTATION WITH CAR T-CELL THERAPY IMPROVES OUTCOMES IN MANAGEMENT OF ADVANCED RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM B-CELL LYMPHOMA

EHA Library, Kai Hu, 325293

LENALIDOMIDE AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PHASE II STUDY

EHA Library, Yan Zhang, 325294

BASELINE TUMOR BURDEN CORRELATES WITH RESPONSE BUT NOT TOXICITIES IN PATIENTS TREATED WITH BISPECIFIC ANTI-CD20, ANTI-CD19 CAR-T CELLS

EHA Library, Joanna Zurko, 325295

IMPACT OF TP53 AND RECURRENT SOMATIC MUTATIONS ON THE OUTCOMES OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T)

EHA Library, Vania Phuoc, 325296

CHIDAMIDE PLUS CHOP VERSUS CHOP AS FRONTLINE TREATMENT IN PERIPHERAL T CELL LYMPHOMA: A RETROSPECTIVE CASE-CONTROL STUDY

EHA Library, Qingqing Cai, 325297

HIGH PREVALENCE OF CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY IN A PEDIATRIC T-CELL LYMPHOBLASTIC LYMPHOMA COHORT

EHA Library, Emma Kroeze, 325298

CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA RECEIVING CONVENTIONAL THIRD-LINE THERAPY: A MULTICENTER, RETROSPECTIVE, REAL-WORLD STUDY IN THE UNITED KINGDOM

EHA Library, Christopher Fox, 325299

EARLY GCSF AFTER ANTI-CD19 CAR T-CELLS DECREASES INCIDENCE OF FEBRILE NEUTROPENIA WITHOUT WORSENING TOXICITIES AND EXPANSION OF CAR T-CELLS IN REFRACTORY/RELAPSED B-CELL LYMPHOMA.

EHA Library, Raphael Lievin, 325300

OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING

EHA Library, John Godwin, 325301

CONCURRENT GAIN/AMPLIFICATION OF MYC, BCL2 AND/OR BCL6 GENES BY FLUORESCENCE IN SITU HYBRIDIZATION: ANOTHER SUBGROUP OF HIGH-GRADE B-CELL LYMPHOMA WITH POOR PROGNOSIS?

EHA Library, Siska Blomme, 325302

VENETOCLAX AS SINGLE AGENT IN BCL2-POSITIVE RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMAS. A PHASE 2 STUDY OF THE FONDAZIONE ITALIANA LINFOMI.

EHA Library, Francesco Zaja, 325303

POLATUZUMAB VEDOTIN IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: INTERIM ANALYSIS.

EHA Library, Olesia Smykova, 325304

RATIONALE FOR TREATMENT SELECTION, AND COMORBIDITIES IN OLDER PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): INSIGHTS FROM REAL WORLD DATA (RWD)

EHA Library, Ashwini Shewade, 325305

VALIDATION OF THE BURKITT LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (BL-IPI) IN PATIENTS FROM TWO CHEMOIMMUNOTHERAPY TRIALS (BURKIMAB-08 AND BURKIMAB-14) BY THE PETHEMA AND GELTAMO GROUPS

EHA Library, Josep Maria Ribera, 325306

EXTRANODAL DISEASE IS AN INDEPENDENT NEGATIVE PREDICTIVE MARKER FOR PROGRESSION-FREE SURVIVAL AFTER CD19-CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Veit Bücklein, 325307

ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE TREATMENT FOR DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Huayuan Zhu, 325308

COMPARISON OF CHIDAMIDE-CONTAINED TREATMENT MODALITIES VERSUS CHEMOTHERAPY IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA

EHA Library, Qingqing Cai, 325309

CELL OF ORIGIN IMPACTS DELTASUVMAX CUTOFF FOR PREDICTION OF RELAPSE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Carolina Feres, 325310

COMPARISON OF IMMUNOCHEMOTHERAPY WITH RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) OR RITUXIMAB-CHOP (R-CHOP) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)

EHA Library, Theodoros Vassilakopoulos, 325311

PREDICTIVE VALUE OF INTERIM FDG-PET/CT SCAN IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA

EHA Library, Veronika Hanáčková, 325312

ESTIMATION OF LONG-TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

EHA Library, Dan Huang, 325313

SAFETY OF AMBULATORY HIGH-DOSE METHOTREXATE (HDMTX) ADMINISTRATION AMONG HEMATOLOGICAL MALIGNANCIES PATIENTS IN TERTIARY CARE CENTER

EHA Library, Maged AL-AMMARI, 325314

OUTCOME OF RITUXIMAB-POLATUZUMAB-BENDAMUSTINE IN THE TREATMENT OF RELAPSED/ REFRACTORY HIGH GRADE LYMPHOMA AND TRANSFORMED HIGH GRADE LYMPHOMA – A MULTI-CENTRE ANALYSIS.

EHA Library, Lydia Sodhi, 325315